Asarfi Hospital Limited · BSE:ASARFI
Asarfi Hospital — Q4 FY2025 Earnings Presentation
27 slides from Asarfi Hospital's earnings presentation, May 8, 2025
Slide 1: Asarfi Hospital Limited
असफ हॉ ीटल सबके िलए ा AHL/AO/2025/859 Date: 08.05.2025 To The BSE Limited The Listing Department 25th Floor, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai-400 001 Sub: Investor Presentation Ref: - Scrip Code: 543943 Dear Sir/ Ma’am, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Dis
Slide 2: Investor Presentation FY 2024-25
Investor Presentation FY 2024-25
Slide 3: Content
1 Company Overview 2 Key Growth Drivers 3 Vision 2027 Content 4 Expansion Plan 5 Leadership Team 6 Financial and Operational Performance 2
Slide 4: Asarfi Hospital: At a Glance
Asarfi Hospital: At a Glance Established in 2005, Asarfi Hospital Limited (AHL) is serving the people of Dhanbad and its neighbouring areas for the last 20 years with affordable and best in class healthcare facilities. Operates two hospitals across Dhanbad region, catering to a dense population of ~
Slide 5: Journey Over The Years
Journey Over The Years • Commenced Operation • Started Construction of Cancer • Started Operations in the of Cardiac Department. Hospital. new Cancer Hospital in Ranguni • Asarfi Hospital • Established Burn • Started Construction of • Installed 20NM3 Oxygen Plant. with capacity of 50 beds and was in
Slide 6: Our Departments and Facilities
Our Departments and Facilities General Paediatrics & Obstetrics & General Cardiology Neurosciences medicine Neonatology Gynaecology Surgery Gastroenterology Orthopaedics Burn & Plastic Oncology Nephrology Urology Surgery Ophthalmology ENT Day Care Dental Physiotherapy Emergency services Sciences Nut
Slide 7: Superspecialty Hospital
Superspecialty Hospital • Location: Situated on the Main Highway, 6 km from Dhanbad Railway Station. • Building: 4 blocks, 6 floors, constructed area of more than 1 Lacs sq. ft., and land area 92 decimals. • Specialty: Cardiology and Neurology together contributes ~40% of revenues whereas General Me
Slide 8: Cancer Hospital
Cancer Hospital • Location: Situated in Ranguni, Dhanbad. • Land Details: Leased 9.55 acres of land from Jharkhand Industrial Area Development Authority (JIADA) for 30 years. • Services: Preventive Oncology, Medical Oncology, Surgical Oncology, Radiation Oncology, Day Care Chemotherapy, Nuclear Medi
Slide 9: Competitive Strengths
Competitive Strengths Advanced high-end medical equipment and technology 01 Equipped with Jharkhand’s first and most advanced Linear Accelerator radiation machine - The Varian True Beam alongside cutting-edge laboratory and imaging equipments. Regional advantage 02 The only cancer hospital in Dhanba
Slide 10: Key Growth Drivers
Key Growth Drivers Eastern India healthcare market Cost effective strategy ➢ Eastern India healthcare market presents a significant ➢ AHL has efficiently operationalized its cancer hospital assets growth opportunity driven by the low penetration of at a capex of less than Rs. 2 lakh per bed, demonst
Slide 11: Vision 2027
20+% Revenue CAGR in next 2 Years Vision 2027 1 11-13% PAT Margin by FY27 Expected Revenue of 6 ~ ₹ 200 Cr by FY27 2 VISION 2027 5 3 15-17% PBT Margin by FY27 500 Beds by FY27 4 23-25% EBITDA Margin by FY27 10
Slide 12: Expansion Plan
Expansion Plan New verticals • Establishing a Bone Marrow Transplant unit in the cancer hospital to strengthen oncology care capabilities. Education Business • A new Healthcare Management and Research Institute under AHL is being designed and under construction in Ranchi, to offer medical and non-me
Slide 13: Leadership Team
Leadership Team Harendra Singh Udai Pratap Singh Sukanti Kumar Das Promoter and CFO Promoter and MD Non- Executive Director • A visionary entrepreneur inspired by the • Renowned Consultant Gynaecologist Company’s Purpose—Health for All. • Started his career in 2017, he is a and brings with him over
Slide 14: Financial and Operational Performance
Financial and Operational Performance 13
Slide 15: Key Highlights
Key Highlights ➢ In Q4’FY25, Consolidated Revenues grew by 41% YoY to ₹ 3,389 lakhs, compared to ₹ 2,404 lakhs in Q4’FY24. ➢ In Q4’FY25, Consolidated EBITDA grew by 28% YoY to ₹ 507 lakhs, compared to ₹ 395 lakhs in Q4’FY24. ➢ In Q4’FY25, Consolidated PAT grew by 1,807% YoY to ₹ 359 lakhs compared t
Slide 16: Financial Highlights (Standalone)
Financial Highlights (Standalone) Total Income (₹ in Lakhs) EBITDA (₹ in Lakhs) and EBITDA Margin % 14,000 3,000 25% 12,000 20% 2,500 20% 10,000 19% 2,000 8,000 15% 1,500 21% 6,000 17% 10% 1,000 15% 4,000 12,813 3,378 3,876 8,607 5% 1,610 2,384 2,000 500 2,363 698 524 400 - - 0% Q4'FY24 Q3'FY25 Q4'F
Slide 17: Financial Highlights (Consolidated)
Financial Highlights (Consolidated) Total Income (₹ in Lakhs) EBITDA (₹ in Lakhs) and EBITDA Margin % 14,000 3,000 25% 20% 12,000 2,500 19% 20% 10,000 2,000 8,000 15% 1,500 21% 6,000 16% 15% 10% 1,000 4,000 12,809 5% 1,605 2,355 3,378 3,871 8,607 2,000 500 695 507 2,363 395 - - 0% Q4'FY24 Q3'FY25 Q4
Slide 18: Revenue Mix Q4'FY24 vs Q4'FY25
Revenue Mix Q4’FY24 vs Q4’FY25 Super-specialty hospital unit 18% 22% Cardiology Cardiology 27% 31% General Medicine General Medicine Neurosciences 5% Neurosciences 1% 4% Department-wise General Surgery Department-wise General Surgery 5% Revenue Mix Q4’FY24 Revenue Mix Q4’FY25 Orthopaedics Orthopaedi
Slide 19: Revenue Mix Q4'FY24 vs Q4'FY25
Revenue Mix Q4’FY24 vs Q4’FY25 Cancer hospital unit 8% 6% 12% 16% Medical Oncology Medical Oncology Surgical Oncology Department-wise Surgical Oncology Department-wise 4% Revenue Mix Q4’FY24 Revenue Mix Q4’FY25 55% Radiation Oncology Radiation Oncology 27% 72% Others* Others* *Others Include: Head a
Slide 20: IPD-OPD Highlights (Both Hospital Units)
IPD-OPD Highlights (Both Hospital Units) IPD-OPD Volumes IPD-OPD Revenues (₹ in Lakhs) 1,20,000 1,14,215 12,000 1,00,000 88,774 9,909 10,000 80,000 8,000 7,061 60,000 6,000 40,000 4,000 29,292 30,690 24,847 2,679 2,440 1,916 1,970 20,000 2,000 1,379 12,467 927 9,530 407 505 2,745 3,324 3,174 0 0 Q4'
Slide 21: Unit Wise ARPOB, Bed Capacity and Occupancy Rate %
Unit Wise ARPOB, Bed Capacity and Occupancy Rate % Super-specialty hospital unit ARPOB (in ₹) Bed Capacity and Occupancy % 25,000 300 64% 62% 60% 61% 250 20,000 200 15,000 150 10,000 100 21,876 21,052 17,177 17,505 5,000 50 250 250 250 250 0 0 Q3'FY25 Q4'FY25 FY24 FY25 Q3'FY25 Q4'FY25 FY24 FY25 ARPO
Slide 22: Surgery Count
Surgery Count Surgery Count Data 2500 146 2000 176 159 178 198 63 1500 193 363 111 266 1000 537 36 459 45 26 44 54 52 500 32 59 43 39 106 53 20 85 645 73 149 526 116 120 165 198 161 0 Q4'FY24 Q3'FY25 Q4'FY25 FY24 FY25 Gen. Surgery Obs & Gyn Orthopedic Neurology Burn & Plastic Surgery ENT Urology 21
Slide 23: Profit and Loss Account (Standalone)
Profit and Loss Account (Standalone) (₹ in Lakhs) Particulars Q4'FY24 Q3'FY25 Q4'FY25 QoQ % YoY % FY24 FY25 YoY % Revenue from operations 2,404 3,289 3,389 3% 41% 8,440 12,057 43% Material costs (584) (718) (750) 4% 28% (2,032) (2,786) 37% Employee benefit expenses (415) (452) (590) 30% 42% (1,413)
Slide 24: Profit and Loss Account (Consolidated)
Profit and Loss Account (Consolidated) (₹ in Lakhs) Particulars Q4'FY24 Q3'FY25 Q4'FY25 QoQ % YoY % FY24 FY25 YoY % Revenue from operations 2,404 3,289 3,389 3% 41% 8,440 12,057 43% Material costs (584) (718) (750) 4% 28% (2,032) (2,786) 37% Employee benefit expenses (415) (453) (592) 31% 43% (1,413
Slide 25: Balance Sheet (Standalone)
Balance Sheet (Standalone) (₹ in Lakhs) Equity and Liabilities FY24 FY25 Assets FY24 FY25 I. EQUITY III. ASSETS 1. Shareholder's funds 1. Non-current assets (a) Share capital 1,968 1,968 (a) Property, plant and equipment 9,371 10,342 (b) Reserves and surplus 5,078 6,176 (b) Non-current investments 1
Slide 26: Balance Sheet (Consolidated)
Balance Sheet (Consolidated) (₹ in Lakhs) Equity and Liabilities FY24 FY25 Assets FY24 FY25 I. EQUITY III. ASSETS 1. Shareholder's funds 1. Non-current assets (a) Share capital 1,968 1,968 (a) Property, plant and equipment 9,377 10,358 (b) Reserves and surplus 5,073 6,131 (b) Non-current investments
Slide 27: Disclosure and Contact Details
Disclosure and Contact Details Certain matters discussed in this presentation may contain statements regarding the company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements do not guarantee future performanc